Showing 41-60 of 498 for: Cochrane Systematic Reviews > Neurologic 
- Anti-hypertensive drugs as disease-modifying agents for Parkinson's disease: evidence from observational studies and clinical trials
Cochrane Systematic Reviews, 20-Sep-2011
Current treatment for Parkinson's disease (PD) is focused on relieving symptoms, at present there is nothing that is widely accepted to halt or slow disease progression. Potential neuroprotective or disease modifying agents have been identified from precl
- Antioxidant treatment for amyotrophic lateral sclerosis or motor neuron disease
Cochrane Systematic Reviews, 10-May-2011
Free radical accumulation and oxidative stress have been proposed as contributing to the progression of amyotrophic lateral sclerosis (or motor neuron disease). A range of antioxidant medications have been studied. This is an updated review.
- Antipsychotic medication for challenging behaviour in people with learning disability
Cochrane Systematic Reviews, 11-Nov-2008
The term 'challenging behaviour', in the absence of psychiatric disorder, encompasses a wide range of behaviours that may be harmful to people or property, may be difficult to manage and may limit access to community facilities. Antipsychotic medications
- Antipsychotic reduction and/or cessation and antipsychotics as specific treatments for tardive dyskinesia
Cochrane Systematic Reviews, 6-Feb-2018
Since the 1950s antipsychotic medication has been extensively used to treat people with chronic mental illnesses such as schizophrenia. These drugs, however, have also been associated with a wide range of adverse effects, including movement disorders such
- Antipsychotics for treatment of delirium in hospitalised non‐ICU patients
Cochrane Systematic Reviews, 18-Jun-2018
Guidelines suggest limited and cautious use of antipsychotics for treatment of delirium where nonpharmacological interventions have failed and symptoms remain distressing or dangerous, or both. It is unclear how well these recommendations are supported by
- Anti‐seizure medications for Lennox‐Gastaut syndrome
Cochrane Systematic Reviews, 7-Apr-2021
Lennox-Gastaut syndrome (LGS) is an age-specific epilepsy syndrome characterised by multiple seizure types, including drop seizures. LGS has a characteristic electroencephalogram, an onset before age eight years and an association with drug resistance.
- Anti‐spasticity agents for multiple sclerosis
Cochrane Systematic Reviews, 20-Oct-2003
Spasticity is a common problem in multiple sclerosis (MS) patients causing pain, spasms, loss of function and difficulties in nursing care. A variety of oral and parenteral medications are available.
- Antithrombotic drugs for carotid artery dissection
Cochrane Systematic Reviews, 6-Mar-2011
Extracranial internal carotid artery dissection (eICAD) is a leading cause of stroke in younger patients.
- Antiviral treatment for Bell's palsy (idiopathic facial paralysis)
Cochrane Systematic Reviews, 5-Sep-2019
Corticosteroids are widely used in the treatment of idiopathic facial paralysis (Bell's palsy), but the effectiveness of additional treatment with an antiviral agent is uncertain. This review was first published in 2001 and most recently updated in 2015.
- Antiviral treatment for preventing postherpetic neuralgia
Cochrane Systematic Reviews, 26-Jan-2014
Postherpetic neuralgia (PHN) is a painful and refractory complication of herpes zoster. Treatments are either partially or totally ineffective for many people with PHN. Antiviral agents, used at the time of the rash, have been proposed as an intervention
- Aromatherapy for dementia
Cochrane Systematic Reviews, 19-Aug-2020
Medications licensed for the treatment of dementia have limited efficacy against cognitive impairment or against the distressed behaviours (behavioural and psychological symptoms, or behaviour that challenges) which are also often the most distressing asp
- Aspirin for vascular dementia
Cochrane Systematic Reviews, 17-Sep-2012
Aspirin is widely prescribed for patients with a diagnosis of vascular dementia. In a survey of UK geriatricians and psychiatrists 80% of patients with clinical diagnoses of vascular dementia were prescribed aspirin. However, a number of queries remain un
- Aspirin with or without an antiemetic for acute migraine headaches in adults
Cochrane Systematic Reviews, 29-May-2019
This is an updated version of the original Cochrane review published in Issue 4, 2010 (Kirthi 2010). Migraine is a common, disabling condition and a burden for the individual, health services and society. Many sufferers choose not to, or are unable to, se
- Atypical antipsychotics for aggression and psychosis in Alzheimer's disease
Cochrane Systematic Reviews, 12-Apr-2012
Aggression, agitation or psychosis occur in the majority of people with dementia at some point in the illness. There have been a number of trials of atypical antipsychotics to treat these symptoms over the last five years, and a systematic review is neede
- Auditory integration training and other sound therapies for autism spectrum disorders (ASD)
Cochrane Systematic Reviews, 7-Dec-2011
Auditory integration therapy was developed as a technique for improving abnormal sound sensitivity in individuals with behavioural disorders including autism spectrum disorders. Other sound therapies bearing similarities to auditory integration therapy in
- Azathioprine for multiple sclerosis
Cochrane Systematic Reviews, 10-Nov-2008
Azathioprine is the most widely used immunosuppressive treatment in multiple sclerosis (MS). It is an alternative to interferon beta for treating MS also because it is less expensive. Concerns about its safety, mainly a possible increased risk of malignan
- Barbiturates for acute traumatic brain injury
Cochrane Systematic Reviews, 12-Dec-2012
Raised intracranial pressure (ICP) is an important complication of severe brain injury, and is associated with high mortality. Barbiturates are believed to reduce ICP by suppressing cerebral metabolism, thus reducing cerebral metabolic demands and cerebra
- Benzodiazepines and related drugs for insomnia in palliative care
Cochrane Systematic Reviews, 22-Nov-2013
Insomnia, a subjective complaint of poor sleep and associated impairment in daytime function, is a common problem. Currently, benzodiazepines are the most used pharmacological treatment for this complaint. They are considered helpful for occasional short-
- Benzodiazepines for alcohol withdrawal
Cochrane Systematic Reviews, 17-Mar-2010
Alcohol abuse and dependence represents a serious health problem worldwide with social, interpersonal and legal interpolations. Benzodiazepines have been widely used for the treatment of alcohol withdrawal symptoms. Moreover it is unknown whether differen
- Benzodiazepines for antipsychotic‐induced tardive dyskinesia
Cochrane Systematic Reviews, 20-Jan-2018
Tardive dyskinesia (TD) is a disfiguring movement disorder, often of the orofacial region, frequently caused by using antipsychotic drugs. A wide range of strategies have been used to help manage TD, and for those who are unable to have their antipsychoti
